- Open
- 43.50
- High
- 43.50
- Low
- 43.50
- Close
- 43.50
- Change
- -1.50 (-3.45%)
- Volume
- 0
⌘K
| 30 Mar 2026 | 07:30:00 | Suspension - Faron Pharmaceuticals Oy |
| 3 Mar 2025 | 12:05:33 | FDA Grants Orphan Drug Designation |
| 28 Feb 2025 | 12:00:00 | Notice of Annual General Meeting |
| 27 Feb 2025 | 07:30:00 | Positive EMA Opinion on Orphan Drug Designation |
Faron's proprietary precision immunotherapy, Bexmarilimab, has the ability to target myeloid cell function and provide long-lasting immune stimulation for challenging cancer types.
| 30 Mar 2026 | 07:30:00 | Suspension - Faron Pharmaceuticals Oy |
| 3 Mar 2025 | 12:05:33 | FDA Grants Orphan Drug Designation |
| 28 Feb 2025 | 12:00:00 | Notice of Annual General Meeting |
| 27 Feb 2025 | 07:30:00 | Positive EMA Opinion on Orphan Drug Designation |
Faron's proprietary precision immunotherapy, Bexmarilimab, has the ability to target myeloid cell function and provide long-lasting immune stimulation for challenging cancer types.
| 27 Feb 2025 | 07:15:01 | Annual Report 2024 published |
| 27 Feb 2025 | 07:15:01 | Annual Report 2024 published |
